PRQR ProQR Therapeutics N.V.

+0  (1%)
Previous Close 4.85
Open 4.85
Price To book 2.01
Market Cap 114.40M
Shares 23,346,000
Volume 32,235
Short Ratio 1.44
Av. Daily Volume 64,958

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b top-line data due mid-2017. Open label data presented at (NACFC) October 27, 2016.
Cystic Fibrosis

Latest News

  1. ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients
  2. ProQR to Present at the Deutsche Bank Health Care Conference
  3. ProQR Announces Annual Meeting of Shareholders
  4. ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU
  5. ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer
  6. ProQR to Present at Two Upcoming Investor Conferences in March
  7. ProQR reports 4Q loss
  8. ProQR Announces Results for the Fourth Quarter and Full Year 2016 and Provides a Business Update
  9. On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day
  10. ProQR to Present at the LEERINK Partners Global Healthcare Conference
  11. Can The Uptrend Continue for ProQR Therapeutics (PRQR)?
  12. How ProQR Therapeutics NV (PRQR) Stacks Up Against Its Peers
  13. Why ProQR Therapeutics (PRQR) Stock Might be a Great Pick
  14. ProQR Therapeutics NV :PRQR-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  15. Blog Coverage ProQR Cystic Fibrosis Drug Meets Primary End Point
  16. Here’s Our Take On The Latest ProQR Therapeutics NV (PRQR) Release
  17. ProQR Jumps on Positive Phase 1 Results
  18. ProQR Cystic Fibrosis Drug Passes First, Early Efficacy Test
  19. ProQR Therapeutics (PRQR) Worth a Look: Stock Up 9.8%